HS-10561
Phase 2Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10561 is one of 13 small molecule programs targeting Chronic Spontaneous Urticaria. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Chronic Spontaneous Urticaria
#DrugCompanyPhaseTrials
1Claritin
PPerrigo Company
Approved
Rhapsido
NovartisPhase 3
Opzelura
PfizerPhase 2
Barzolvolimab
CCelldex Therapeutics
Phase 3
ICP-332
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
JYB1904
JJemincare
Phase 3
LOU064
NovartisPhase 3
CM512
KKeymed Biosciences Co.Ltd
Phase 2
Human Interleukin-2 (IL-2) (proleukin)
NNova Scotia Health Authority
Phase 3
CMAB007
TTaizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-10561. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details